Pawel F. Mielnik

Forde, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Journal: RMD open

Published: October 28, 2025

Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug-Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population.

Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug-Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population.

Journal: The Journal of rheumatology

Published: August 06, 2025

Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network.

Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network.

Journal: The Journal of rheumatology

Published: January 02, 2025

Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis.

Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis.

Journal: Joint bone spine

Published: June 17, 2024

Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased.

Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased.

Journal: BMC medical research methodology

Published: November 28, 2023

Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD).

Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD).

Journal: Rheumatology advances in practice

Published: January 26, 2023

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010-2019).

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010-2019).

Journal: BMC health services research

Published: December 14, 2022

Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD.

Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD.

Journal: The Journal of rheumatology

Published: November 03, 2022

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Journal: JAMA

Published: December 21, 2021

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs.

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs.

Journal: BMC health services research

Published: October 20, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026